Evidence map›Paper›PMID 42212149›Full record

ArticleFrontiers in immunology2026

Broadly neutralizing antibody-secreting CAR-T cells elicit Fc-mediated effector functions

Zoe Stylianidou, Sarah Gerlo, Magdalena Wejda, Elianne Burg, Evelien De Smet, Ytse Noppe, Maxime Verschoore, Jolien Van Cleemput, Linos Vandekerckhove, Wojciech Witkowski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zoe StylianidouHIV Cure Research Center, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.
Sarah GerloHIV Cure Research Center, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.
Magdalena WejdaHIV Cure Research Center, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.
Elianne BurgHIV Cure Research Center, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.
Evelien De SmetHIV Cure Research Center, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.
Ytse NoppeHIV Cure Research Center, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.
Maxime VerschooreHIV Cure Research Center, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.
Jolien Van CleemputHIV Cure Research Center, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.
Linos VandekerckhoveHIV Cure Research Center, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.
Wojciech WitkowskiHIV Cure Research Center, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite significant advances in antiretroviral therapy (ART), human immunodeficiency virus (HIV) persists in long-lived viral reservoirs, requiring lifelong treatment and highlighting the need for curative strategies. Viral persistence across anatomically distinct reservoirs, together with HIV-associated immune dysregulation, supports the development of combination immunotherapies capable of acting through multiple antiviral mechanisms. Here, we developed and evaluated a Hybrid chimeric antigen receptor (CAR) platform that combines the targeted cytotoxicity of CAR-T cells with the secretion of broadly neutralizing antibodies (bNAbs). We assessed the capacity of Hybrid CAR-T cells to eliminate HIV-infected cells, neutralize free virus, and recruit Fc-mediated effector mechanisms

Indexed as

Broadly Neutralizing AntibodiesHIV-1HIV AntibodiesHIV InfectionsImmunoglobulin Fc FragmentsImmunotherapy, AdoptiveReceptors, Chimeric AntigenAnimalsAntibody-Dependent Cell CytotoxicityCD4-Positive T-LymphocytesDisease Models, AnimalHumansMiceBroadly Neutralizing AntibodiesHIV AntibodiesImmunoglobulin Fc FragmentsReceptors, Chimeric AntigenADCCADCPbroadly-neutralizing antibodiesCAR-T cellsHIV

Identifiers

PMID42212149
PMCPMC13214270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.